382MO Updated results from the phase I/II study of OP-1250, an oral complete estrogen receptor (ER) antagonist (CERAN) and selective ER degrader (SERD) in patients (pts) with advanced or metastatic ER-positive, HER2-negative breast cancer
| Autor: | Lin, N.U., Borges, V.F., Patel, M.R., Okera, M., Meisel, J., Wesolowski, R., Pluard, T., Miller, K.D., McCarthy, N.J., Conlin, A.K., Mahtani, R., Sabanathan, D., McCann, K.E., Roesch, E., Mathauda-Sahota, G., Schroeder, J., Hamilton, E.P. |
|---|---|
| Zdroj: | In Annals of Oncology October 2023 34 Supplement 2:S338-S338 |
| Databáze: | ScienceDirect |
| Externí odkaz: |
|